Genmab vets at low-profile Y-mAbs steer two MSK cancer drugs to the FDA after landing $50M from HBM
Almost exactly two years ago, a group of Genmab veterans formed a biotech company called Y-mAbs in New York, launching with a pair of clinical …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
